Rapid Absorption and Easy Intake, All in One

Yuhan Corporation announced on February 19 that it has launched a new over-the-counter product, "Ribeolla," for adjunctive therapy in patients with liver disease and for adults who need liver health management.


Ribeolla is a liquid-form adjunctive therapy for liver disease developed by scientifically combining key ingredients involved in liver cell protection and metabolic processes, and is characterized by providing both rapid absorption and high convenience of intake. Ribeolla was developed not only for the purpose of adjunctive therapy for patients with impaired liver function, but also for adults who need liver health management for various reasons such as frequent alcohol consumption, a high-fat diet, elevated liver enzyme levels, and chronic fatigue.

Yuhan Corporation's liquid-form adjunctive treatment for liver disease 'Ribeoolla'. Yuhan Corporation

Yuhan Corporation's liquid-form adjunctive treatment for liver disease 'Ribeoolla'. Yuhan Corporation

View original image

Ribeolla contains a balanced combination of ingredients that are closely related to liver function, including L-arginine, betaine, and citric acid hydrate. L-arginine is an amino acid that plays an important role in protein metabolism and ammonia detoxification and can help improve nitrogen metabolism in patients with impaired liver function. Betaine has attracted attention in studies related to fatty liver and liver damage and is known to inhibit fat accumulation in liver cells and contribute to methylation processes. Citric acid hydrate functions as a cofactor in energy metabolism and is regarded as an ingredient that helps improve the overall efficiency of liver metabolism. Yuhan Corporation explained that it maximized the mechanistic, complementary effects for improving liver function by combining these three ingredients in an optimal ratio.


Another differentiating feature of Ribeolla is its "satgat cap" packaging applied together with the liquid formulation. The satgat cap is designed to be easily opened with one hand, allowing elderly consumers or those with weak grip strength to use the product conveniently. Compared with powder or tablet forms, it offers faster absorption into the body, while reducing the inconvenience of the opening process and thereby further enhancing ease of administration. It is easy to carry, which reduces restrictions on when and where it can be taken, and it has been designed so that busy modern consumers can incorporate it naturally into their daily routines.


A Yuhan Corporation official said, "Ribeolla reflects the recent trend of growing preference for liquid-form adjunctive therapies for liver disease by enhancing both absorption efficiency and convenience of intake," adding, "By applying the satgat cap, we have improved opening convenience as well, achieving differentiation across the entire real-world user experience."



Ribeolla is an over-the-counter medicine and can be purchased at pharmacies.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing